<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820091</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-FUS-12-103</org_study_id>
    <nct_id>NCT01820091</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®</brief_title>
  <official_title>An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn® (Pralatrexate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related
      Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, uncontrolled, nonrandomized, multicenter, dose-finding, single-arm,
      Phase 1 study primarily to determine the optimal dose and schedule of Fusilev to prevent or
      reduce Folotyn-related Grade 3 or higher oral mucositis.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose and Schedule of Fusilev to prevent or reduce Oral Mucositis</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>The study period will begin on the first day of Folotyn treatment (Day 1). Folotyn will be administered intravenously (IV) at a dose of 190 mg/m2 on Days 1 and 15 in a 28-day treatment cycle. Twenty-four hours after the Folotyn dose, Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned. Within a given cohort, Fusilev will be administered at the same dose and schedule after each Folotyn dose for the duration of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of Fusilev on the number of Folotyn-related dose modifications secondary to oral mucositis</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Fusilev on the frequency of Oral Mucositis</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Fusilev on use of Analgesics for Oral Mucositis</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Fusilev on number of Folotyn doses delivered</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Fusilev - 20 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle
Days 2 and 16: 4 doses/day
Days 3 and 17: 4 doses/day
Days 4 and 18: 2 doses/day
Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Fusilev - 12 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.
Fusilev dose to start 24 hours after Folotyn dose.
Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Fusilev - 8 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.
Fusilev dose to start 24 hours after Folotyn dose.
Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 - Fusilev - 4 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.
Fusilev dose to start 24 hours after Folotyn dose.
Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 - Fusilev - 2 doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle
Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folotyn</intervention_name>
    <description>A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.</description>
    <arm_group_label>Cohort 1 - Fusilev - 20 doses</arm_group_label>
    <arm_group_label>Cohort 2 - Fusilev - 12 doses</arm_group_label>
    <arm_group_label>Cohort 3 - Fusilev - 8 doses</arm_group_label>
    <arm_group_label>Cohort 4 - Fusilev - 4 doses</arm_group_label>
    <arm_group_label>Cohort 5 - Fusilev - 2 doses</arm_group_label>
    <other_name>Pralatrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fusilev</intervention_name>
    <description>Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.</description>
    <arm_group_label>Cohort 1 - Fusilev - 20 doses</arm_group_label>
    <arm_group_label>Cohort 2 - Fusilev - 12 doses</arm_group_label>
    <arm_group_label>Cohort 3 - Fusilev - 8 doses</arm_group_label>
    <arm_group_label>Cohort 4 - Fusilev - 4 doses</arm_group_label>
    <arm_group_label>Cohort 5 - Fusilev - 2 doses</arm_group_label>
    <other_name>Levoleucovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) after at least one line of
             therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Histologically or cytologically confirmed Stage III B/IV NSCLC

          -  Adequate hematological, hepatic, and renal function

          -  Available during the first 8 weeks of the study treatment period to visit the clinic
             for oral Mucositis assessments on scheduled days

        Exclusion Criteria:

          -  Active concurrent malignancy. If there is a history of prior malignancies other than
             those exceptions listed above, the patient must be disease-free for at least 5 years

          -  Congestive heart failure

          -  Uncontrolled hypertension

          -  Known human immunodeficiency virus (HIV)-positive diagnosis

          -  Previous exposure to Pralatrexate

          -  Pregnant or breast-feeding women

          -  Major surgery within 14 days of enrollment

          -  Active uncontrolled infection, underlying medical condition, or other serious illness
             that would impair the ability of the patient to receive protocol treatment

          -  Symptomatic central nervous system (CNS) metastases or lesions for which treatment is
             required. Patients who received prophylactic CNS treatment are eligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminopterin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

